Cadence Pharmaceuticals™

Canaccord Adams' 28th Annual Global Growth Conference

August 12, 2008 at 9:00 AM ET

InterContinental Hotel in Boston

Theodore Schroeder, President and CEO

Return to Events & Presentations.

Forward-Looking Statements
Cadence cautions you that statements included in the company's conference calls, press releases and other materials posted on, or available through, this website that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those discussed in the conference calls, press releases and other materials posted on, or available through, this website due to the risks and uncertainties inherent in Cadence's business including, without limitation: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent regulatory approval, product development or commercialization, or that could result in recalls or product liability claims; maintenance and enforcement of Cadence's licensing arrangements with various third party licensors; the scope and validity of patent protection for its product candidates; and other risks detailed in Cadence's Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of such conference calls, press releases and other materials. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update such statements to reflect events or circumstances after the date made. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Print page Print
Email page Email


Stock Quote
CADX - (NASDAQ)
$8.70   + 0.03
Nov 20, 2009
4:12 PM ET

Quotes delayed at
least 20 minutes.
Information provided
by eSignal.